Search filters

Filters
Clear All

Phase

  • 24
  • 4
  • 23
  • 1
  • 31
  • 1
  • 10
  • 97
  • 62
  • 1
  • 1
  • 95

Found 97 Vision Loss trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 A Phase 2  Randomized  Placebo-Controlled Study of Safety and Efficacy Following Repeat-Dose Administration of Evinacumab (anti-ANGPTL3) in Patients with Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
99 years or below
All genders
Phase 2
A phase 2, randomized, placebo-controlled study designed to evaluate the efficacy and safety of repeated doses of evinacumab in adult patients with severe hypertriglyceridemia. The study consists of screening period (up to 37 days), a baseline/single-blind placebo run in period, a 12-week double-blind treatment period, a single-blind 12 week treatment …
 A Randomized  Double-blind  Placebo-controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
99 years or below
All genders
Phase 3
This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter, international, parallel-group study to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo (1:1) in participants with symptomatic oHCM. Approximately 220 participants will be enrolled. This includes ~80 participants (~40 per treatment group) who consent to participate in a …
99 years or below
All genders
Phase 2
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
99 years or below
All genders
This is a multi-center, randomized, double-blind, placebo-controlled study of safety and efficacy of ISIS 678354 in patients with FCS. Eligible patients will enter an approximately 4-week Screening Period and an approximately 2-week qualification period. Approximately 60 eligible patients will be randomized 1:1 to Cohort A (50 mg) or Cohort B …
 A Randomized  Double-Blind  Parallel  Placebo-Controlled Study of the Efficacy  Safety and Tolerability of Dupilumab in Adult Patients with Active Eosinophilic Esophagitis
1 years - 99 years
All genders
Phase 2
This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group, proof-of-concept study. The primary purpose of this study is to evaluate the effect of dupilumab on relieving EoE clinical symptoms and reducing esophageal inflammation in adults. Currently there is no regulatory-approved endpoint for drug registration for this indication. Published clinical trials …
 A Phase 3  Double-Blind  Randomized  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
99 years or below
All genders
Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis
 MG0003  A Phase 3  Randomized  Double-Blind  Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis
18 years - 99 years
All genders
Phase 3
This is a Phase 3 study of rozanolixizumab in anti-AChR or anti-MuSK autoantibody-positive patients with generalized MG who experience moderate to severe symptoms and are being considered for treatment with IVIg or PEX. The primary objective of the study is to demonstrate the clinical efficacy of rozanolixizumab in patients with …
99 years or below
All genders
This is a multicenter, randomized, double-blind, placebo-controlled two-part trial in patients with FAP who have previously undergone a colectomy/proctocolectomy using the invesitgational product REC-4881.